Chugai Pharmaceutical Co Ltd was established on March 8, 1943. The Company is engaged in the manufacture, sale, import and export of pharmaceutical products. Its branches are located in Sapporo, Sendai, Tokyo Branch 1, Tokyo Branch 2, Yokohama, Nagoya, Kyoto, Osaka, Hiroshima, Takamatsu and Fukuoka. The Company has research laboratories at Fuji-Gotemba, Kamakura and Ukima. Its products in oncology include Kytril, Femara, Tarceva, Xeloda, Neutrogin, Rituxan, Herceptin, and Avastin; bone and joint disease products comprise Edirol, Alfarol, Suvenyl, Evista, and Actemra; and renal disease products consist of Renagel, Oxarol, Epogin, and Mircera. The Company also provides products for chronic hepatitis C, which include Copegus, CellCept, Pegasys, Sigmart, and Tamiflu. In addition, it has various development, product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, and other diseases.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.